April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Genotypic Analysis Of Treatment Response To Anti-vegf Therapy In Age-related Macular Degeneration
Author Affiliations & Notes
  • Sara Bozorg
    Ophthalmology, Univ of California-San Diego, San Diego, California
  • Seanna Grob
    Ophthalmology, Univ of California-San Diego, San Diego, California
  • G Hughes
    Ophthalmology, Univ of California-San Diego, San Diego, California
  • Mark H. Nelson
    North Carolina Macular Consultants, Winston-Salem, North Carolina
  • Paul E. Tournambe
    Ophthalmology, Retina Consultants La Jolla, San Diego, California
  • Michael H. Goldbaum
    Ophthalmology, Univ of California-San Diego, San Diego, California
  • Henry A. Ferreyra
    Ophthalmology, Univ of California-San Diego, San Diego, California
  • William R. Freeman
    Ophthalmology, UCSD Jacobs Retina Center, La Jolla, California
  • Igor Kozak
    Ophthalmology, Univ of California-San Diego, San Diego, California
  • Kang Zhang
    Ophthalmology, Univ of California-San Diego, San Diego, California
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 5242. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Sara Bozorg, Seanna Grob, G Hughes, Mark H. Nelson, Paul E. Tournambe, Michael H. Goldbaum, Henry A. Ferreyra, William R. Freeman, Igor Kozak, Kang Zhang; Genotypic Analysis Of Treatment Response To Anti-vegf Therapy In Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2011;52(14):5242.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate whether genotype can help predict an individual’s response rate to anti-VEGF therapy in the setting of exudative age-related macular degeneration (AMD).

Methods: : A retrospective chart review was performed on 264 patients treated with anti-VEGF for exudative AMD. Five single nucleotide polymorphisms (SNPs) - rs2274700 and rs1061170 in CFH, rs17611 in C5, rs2230199 in C3 and rs9332739 in C2 - were genotyped using the SNaPshot method. Visual acuity and spectral domain optical coherence tomography (SD-OCT) were used to determine clinical response. The patients were considered non-responders to anti-VEGF therapy if their visual acuity did not improve by 1 ETDRS line or if their foveal thickness did not decrease as a result of therapy. Chi-squared tests were used for analysis of genetic data.

Results: : We reviewed the data of 264 patients treated with anti-VEGF for exudative AMD. Of these, 112 patients were found to be responders to anti-VEGF and 152 patients were considered non-responders. There was no statistically significant correlation with responsiveness to anti-VEGF therapy and the presence of at risk or protective AMD alleles in the genetic variants tested.

Conclusions: : Candidate risk or protective alleles for AMD were not associated with treatment response. Further studies on more candidate genes and a genome wide study will aid identification of the genetic underpinnings in anti-VEGF response and maximize patient benefit through personalized medicine.

Keywords: age-related macular degeneration • genetics • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×